Article History
Received: 3 February 2021
Accepted: 25 May 2021
First Online: 4 June 2021
Ethics approval and consent to participate
: This clinical field study was conducted in compliance with local and national regulatory requirements in Germany, Hungary and Spain and consistent with the principles of Good Clinical Practices (VICH guideline on good clinical practice [GCP; VICH GL 9]) and Directive 2001/82/EC as amended; the Rules Governing Medicinal Products in the European Union, Volume VIIA: Guidelines for the testing of veterinary medicinal products: Demonstration of Effectiveness of Ectoparasiticides, 7AE17a, page 215–222; EMEA/CVMP/EWP/ 005/2000-Rev.2: Guideline for the testing and evaluation of the effectiveness of antiparasitic substances for the treatment and prevention of flea and flea infestation in dogs and cats, 12 Nov 2007; and with the guidelines of the World Association for the Advancement of Veterinary Parasitology. Participating dog owners were required to sign an informed consent form for their dog(s) to participate in the study after details of the study design and products under investigation had been explained.
: Not applicable.
: These studies were funded by Elanco Animal Health. All authors are current or former employees of Elanco Animal Health. The handling editors have been involved in consulting services (Filipe Dantas-Torres), research projects (Pablo Jesús Borrás, Filipe Dantas-Torres, Adnan Hodžić) and meetings (Filipe Dantas-Torres) sponsored by different veterinary pharmaceutical companies in the past 10 years, including Elanco. They declare that each manuscript in this collection was handled impartially and peer reviewed rigorously by at least two independent external reviewers.